| Clinical data | |
|---|---|
| Other names | 6α-Methylpregn-4-ene-3,20-dione; 6α-MP; 6-MP; 6MP; NSC-75530 |
| Drug class | Progestogen;Progestin |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H32O2 |
| Molar mass | 328.496 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6α-Methylprogesterone (6α-MP) is aprogestin which was never marketed.[1][2][3][4][5][6][7] It has 150% of theprogestogenicpotency ofprogesterone.[5] In addition, and in contrast to progesterone, 6α-MP has weakandrogenic,antiandrogenic, andsynandrogenic actions.[5] 6α-MP is structurally related tomedroxyprogesterone acetate (MPA; 6α-methyl-17α-acetoxyprogesterone) andmegestrol acetate (MGA; 6-dehydro-6-methyl-17α-acetoxyprogesterone), which possess androgenic and/or antiandrogenic activity to varying degrees similarly.[5] MPA is more androgenic than 6α-MP and MGA.[5]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |